Coronary Artery Disease Clinical Trial
Official title:
ARgentinean Risk Assessment Registry in Acute Coronary Syndrome; the ARRA-RACS Study.
The first aim of this trial is to assess the long-term prognostic value of Omega-3 index,
which is a measure of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) relative to
other fatty acids in the erythrocyte membrane, in an unselected, regional multicenter
observational study of 982 chest pain patients admitted to the emergency unit, employing
blood samples collected at admission.
The second purpose of this study is to evaluate the prognostic utility of vitamin D in the
same population.
The third purpose of this study is to assess the incremental prognostic value of B-type
natriuretic peptide (BNP) and high-sensitive C-reactive protein (hsCRP).
BACKGROUND Cardiac troponins are sensitive markers for myocardial injury in ACS and even a
minor elevation of cardiac troponins is associated with an increased risk for future adverse
coronary events. However, a detectable troponin release occurs only in a part of patients
admitted with ACS. The clinical outcomes and further prognosis of patients with ACS with
absent TnT release vary widely, and the identification of potential high-risk patients with
troponin negative ACS still remains a major problem in clinical routine. Therefore, the aim
of this study is focused on identifying new biomarkers for risk stratification.
Omega- 3 Index: The value of the Omega-3 Index as a prognostic marker in the acute coronary
syndromes is still under investigation.
Vitamin D deficiency is positively correlated with cardiovascular risk and N-3
polyunsaturated fatty acids (PUFA's) may reduce the risk of cardiovascular disease. Vitamin
D can either be ingested, or created in the skin on exposure to sun, whereas PUFA's are
largely incorporated through the diet. Vitamin D deficiency in humans is increasing and its
levels are influenced by the color of the skin, geographical location, latitude, altitude,
season and daytime.
In addition to Vitamin D, several studies have shown that, N-3 polyunsaturated fatty acids
(PUFA's), also have a positive impact on the cardiovascular system. PUFA's are not
sufficiently synthesized in the body and are incorporated through the diet. These essential
fatty acids are found almost exclusively in oily fish, and have been shown to have a
positive impact on several cardiovascular risk factors.
Fish, a source of both Vitamin D and omega-3, is frequently consumed by the costal
population of Norway, and is less preferred by the inland beef-consuming population in
Northern Argentina. The subtropical location and altitude of Salta, Argentina, is associated
with a higher exposure to sun in comparison to the temperate location of Norway. The uptake
of Vitamin D in the costal population of Norway may essentially be through the diet, whereas
sun exposure may be the essential source of Vitamin D in the Northern Argentinean
population.
By investigating the correlation between omega-3 and Vitamin D, we may better understand the
nutritional impact on Vitamin D and its correlation with n-3 PUFA's.
B-type natriuretic peptide: B-type natriuretic peptide (BNP) is a counter-regulatory peptide
hormone predominantly synthesized in the ventricular myocardium. BNP is released into the
circulation in response to ventricular dilatation and pressure overload, and reflects
ventricular wall stress and tissue hypoxia rather than cell injury per se. It is a well
known marker of left ventricular dysfunction and heart failure (HF), and it provides
prognostic information beyond and above left ventricular ejection fraction (LVEF) in
patients with an acute coronary syndrome (ACS). This marker of neurohormonal activation and
inflammation plays a pivotal role across the spectrum of ACS, including patients with
ST-elevation myocardial infarction (MI) and non ST-elevation ACS (NSTE-ACS). Previous
studies have demonstrated that BNP measured in the first days after the onset of symptoms
independently predicts mortality, HF, and new MI in this patient population. Elevated
natriuretic peptides at presentation have been shown to identify patients with ACS who are
at higher risk of death and HF, and it adds information to that provided by the troponins.
However, in a low-risk population the association between elevated BNP and survival is
attenuated when adjustment is made for echocardiographic variables (in addition to clinical
covariates), as shown by Wang and colleagues. In addition, they did not find any association
between baseline BNP and the risk of coronary heart disease (CHD).
High-sensitive C-reactive protein (hsCRP): C-reactive protein (CRP) is an acute-phase
reactant that is produced in response to acute injury, infection or other inflammation
stimuli. It is a marker for underlying systemic inflammation and plays an important role in
the initiation and propagation of atherosclerosis and ultimately to plaque rupture and the
ensuing thrombotic complication. Elevated levels of CRP were first reported in patients
hospitalized with NSTE-ACS in the early 1990s. Through the use of appropriate high-sensitive
assays, it has been possible to investigate the relationship between plasma CRP levels that
previously were considered to be normal and cardiovascular disease (CVD). Nevertheless, it
is still under debate which markers should be preferred for risk prediction. It has been
suggested that the combined evaluation of BNP and CRP may yield incremental prognostic
information in the risk stratification of patients with ACS, and their combined use has been
shown to improve long-term risk prediction of mortality in patients with stable CHD. To our
knowledge, there are limited data available that directly compare these two markers in a
prospective manner in an unselected patient population presenting to the emergency
department (ED) with chest pain. In addition, their role in risk stratification in patients
with ACS is still under evaluation, and therefore additional investigations are necessary.
STUDY DESIGN This prospective regional multicenter observational non-invasive trial includes
982 men and women admitted with chest pain and potential ACS at nine hopitals in Salta,
Argentina between November 2005 and November 2008. Blood samples were collected immediately
following admission. Patients were stratified according to peak troponin T (TnT) release
following admission; i.e. 1) patients with an admission TnT exceeding 0.01 ng/mL, and 2)
patients with a TnT level below 0.01 ng/mL.
Assessment of a history of previous MI, angina pectoris (AP), congestive heart failure
(CHF), diabetes mellitus and arterial hypertension was based on hospital records and
personal interview. Electrocardiographic findings at admission were classified according to
the presence of ST segment changes.
Written informed consent was obtained from all patients. Survival status, date and cause of
death and clinical data were obtained by telephone interview and hospital journal reports at
4 predefined time points (30 days, 6, 12 and 24 months) during the two year follow-up
period. In case of incapacity to provide information, the general practitioner or nursery
home were contacted for relevant data. Hospital journals were searched for confirmation of
reported data.
DATA OWNERSHIP AND PUBLICATION OF RESULTS. The ARRA-RACS Steering Committee has the
ownership of all data registered in the ARRA-RACS database, and any use of these data
including the preparation and publication of scientific reports must be approved by the
Steering Committee. Scientific articles will be published by ARRA-RACS investigators or by
authors mentioned by name. The author sequence should be approved by the Steering Committee
and based upon contribution. Incentives to involve articles as part of a doctoral thesis
should be encouraged. All collaborators in the study will be mentioned by name in an
Appendix section of the main article from the study. The results will be published in
peer-reviewed scientific journals and in magazines for the general public.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |